Interference by DOPAC and ascorbate during attempts to measure drug-induced changes in neostriatal dopamine with Nafion-coated, carbon-fiber electrodes.
The selectivity of Nafion-coated, carbon-fiber electrodes was evaluated for the voltammetric detection of dopamine in the presence of 3,4-dihydroxyphenylacetic acid (DOPAC) and ascorbate, which are interferant anions in the brain. Nafion coating was applied to both polished carbon-disk electrodes and electrochemically modified electrodes. During in vitro testing, polished disk electrodes showed the greatest selectivity for dopamine at the fastest scan rate tested (300 V s-1), but the drift in signal made slow changes in dopamine difficult to determine. Electrochemically modified electrodes already provide an ascorbate wave distinct from that for dopamine, but Nafion coating actually decreased dopamine selectivity with respect to DOPAC. In vivo testing was carried out in the neostriatum of urethane-anesthetized rats in response to drug- or stimulation-induced increases in dopamine transmission. Administration of haloperidol (0.5 mg kg-1) followed by GBR 12909 (20 mg kg-1), which is known to cause a 10-fold increase in extracellular dopamine, failed to produce a selective signal for dopamine when measured voltammetrically. Comparable results were obtained following administration of amphetamine (2.5 mg kg-1), which also increases dopamine overflow. Voltammetric detection of dopamine was possible, however, during electrical stimulation of dopaminergic afferents in the medial forebrain bundle. Thus, voltammetry with Nafion-coated electrodes is best suited to the measurement of transient changes in extracellular dopamine rather than the relatively prolonged changes in dopamine overflow produced by various drugs.
Wiedemann
D J
DJ
Program in Neural Science, Indiana University, Bloomington 47405.
Basse-Tomusk
A
A
Wilson
R L
RL
Rebec
G V
GV
Wightman
R M
RM
D015102:3,4-Dihydroxyphenylacetic Acid; D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001205:Ascorbic Acid; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002244:Carbon; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000032:analysis / Q000378:metabolism*; D004558:Electric Stimulation; D004563:Electrochemistry / Q000295:instrumentation / Q000379:methods; D004566:Electrodes; D005465:Fluorocarbon Polymers; D006220:Haloperidol / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D005465:Fluorocarbon Polymers; D014179:Neurotransmitter Uptake Inhibitors; D010879:Piperazines; D015102:3,4-Dihydroxyphenylacetic Acid; C040402:perfluorosulfonic acid; D002244:Carbon; C043425:vanoxerine; D000661:Amphetamine; D006220:Haloperidol; D001205:Ascorbic Acid; D004298:Dopamine